## UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA

IN RE: TYLENOL (ACETAMINOPHEN) MARKETING, SALES PRACTICES AND PRODUCTS LIABILITY LITIGATION	§ MDL NO. 2436	
	§ 2:13-md-02436	
	§ § HON. LAWRENCE F. STENGEL	
This Document Relates to:		
	Civil Action No. 2:12-cv-07263	
	\$ §	
Rana Terry, as Personal Representative	\$ \$	
and Administrator of the Estate of Denice	s S	
Hayes, Deceased,	8 8	
	8 8	
Plaintiff,	5 §	
X.	s §	
V.	\$	
McNEIL-PPC, Inc., McNeil Consumer	§	
Healthcare, and Johnson & Johnson, Inc.,	§	
realized e, and somison & somison, me.,	§	
Defendants.	§	

Defendants.

## CASE MANAGEMENT ORDER NO. 18(h) (1<sup>st</sup> Bellwether Case Scheduling Order)

AND NOW, on this <u>12th</u> day of July, 2015, after a telephone conference with

lead counsel and upon consideration of correspondence from counsel regarding

scheduling, it is hereby **ORDERED** that:

- The trial date of October 26, 2015 is CONTINUED generally.<sup>1</sup> After pre-trial motions have been resolved, the court will confer with counsel about scheduling a new trial date.
- 2) Deadlines for Motions on Confidential/Highly Confidential Information Usage at Trial, Proposed Jury Instructions, Trial Witness Lists, and Jury Questionnaires are VACATED.<sup>2</sup> After pre-trial motions have been resolved, the court will confer with counsel about setting new deadlines for submitting these pre-trial materials.
- 3) The "Deposition Designations" section (para. 3) of Case Management Order (CMO) 18(c)<sup>3</sup> and CMO 18(d)<sup>4</sup> are VACATED. After pre-trial motions have been resolved, the court will confer with counsel about setting new deadlines for submitting Deposition Designations.

All other provisions of CMO 18(c) and subsequent revisions of CMO 18 remain unchanged.

## BY THE COURT:

/s/Lawrence F. Stengel LAWRENCE F. STENGEL, J.

<sup>&</sup>lt;sup>1</sup> <u>See</u> Case Management Order (CMO) 18(c)(13-md-2436, Doc. No. 202; 12-cv-7263, Doc. No. 39 entered on May 5, 2015).

<sup>&</sup>lt;sup>2</sup> <u>See</u> "Motions Practice" section (para. 2) of CMO 18(c)(13-md-2436, Doc. No. 202; 12-cv-7263, Doc. No. 39 entered on May 5, 2015).

<sup>&</sup>lt;sup>3</sup> <u>See</u> 13-md-2436, Doc. No. 202; 12-cv-7263, Doc. No. 39 entered on May 5, 2015.

<sup>&</sup>lt;sup>4</sup> See 13-md-2436, Doc. No. 207; 12-cv-7263, Doc. No. 40 entered on May 18, 2015.